Ironwood Pharmaceuticals
IRWD
223 hedge funds and large institutions have $727M invested in Ironwood Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 77 increasing their positions, 77 reducing their positions, and 37 closing their positions.
72,380% more call options, than puts
Call options by funds: $50.7M | Put options by funds: $70K
11% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 37
8% more capital invested
Capital invested by funds: $674M → $727M (+$53.7M)
1% more funds holding
Funds holding: 221 → 223 (+2)
0.28% more ownership
Funds ownership: 102.34% → 102.61% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.14M |
| 2 |
Millennium Management
New York
|
+$5.09M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.67M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$4.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.46M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$3.94M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.61M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
-$2.4M |
IRWD Hedge Fund Activity: Q4 2024 in Review
223 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2024, worth a combined $727M — up 8% from $674M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IRWD positions and 37 closed out — a net gain of 4 holders — while 77 added to existing stakes and 77 trimmed.
The largest buyer was Armistice Capital, adding an estimated $5.14M. The largest seller was Vanguard Group, cutting an estimated $10.1M.
- 223 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2024, up from 221 in Q3 2024.
- Funds reported $727M of Ironwood Pharmaceuticals stock for Q4 2024, up 8% quarter-over-quarter.
- 41 funds opened new Ironwood Pharmaceuticals positions in Q4 2024 and 37 closed out, a net change of +4 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2024 was Armistice Capital, an estimated $5.14M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2024 was Vanguard Group, an estimated $10.1M sold.
Based on aggregated 13F filings for Q4 2024.